Scholarlink

Background <p>Renal artery stenosis (RAS) is a major cause of atherosclerotic secondary hypertension, and interventional therapy carries notable risks. This study evaluated the effects of the PCSK9 inhibitor evolocumab plus statin therapy on lipid profiles, renal artery hemodynamics, and renal function in patients with coronary artery disease (CAD) and RAS.</p> Methods <p>In this single-center retrospective cohort, 57 CAD patients with RAS (July 2019–May 2025) underwent bilateral renal artery ultrasonography and ≥ 1 month follow-up. Patients received either PCSK9 inhibitor therapy (<i>n</i> = 25; evolocumab 140&#xa0;mg biweekly + atorvastatin 20&#xa0;mg/day) or standard statin therapy alone (<i>n</i> = 32; atorvastatin 20&#xa0;mg/day as control). Changes in LDL-C, TC, TG, Lp(a), serum creatinine (Cr), and RAU_RRA/RAU_LRA were compared. Analyses included hierarchical clustering, principal component analysis (PCA), t-tests, and Spearman correlation.</p> Results <p>Between-group comparisons after treatment showed that the combination therapy group was significantly superior to the control group in terms of lipids, creatinine, and renal artery parameters (all <i>P</i> &lt; 0.05), while Lp(a) showed an increasing trend. Within-group pre-post comparisons showed improving trends in various indicators, but only some lipid parameters reached statistical significance.</p> Conclusion <p>In this exploratory study, evolocumab plus statin was associated with improved lipids, renal artery hemodynamics, and potential renal benefit. Due to the small sample size, non-randomized design, and non-significant within-group creatinine change, results should be interpreted cautiously and validated in prospective studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical observation of renal artery stenosis treated with PCSK9 inhibitor

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月2日

查看全文
  • Fali Zhao,
  • Qianping Gao,
  • Bo Jiang,
  • Han Li,
  • Yawen Wu,
  • Wei Yang

摘要

Background

Renal artery stenosis (RAS) is a major cause of atherosclerotic secondary hypertension, and interventional therapy carries notable risks. This study evaluated the effects of the PCSK9 inhibitor evolocumab plus statin therapy on lipid profiles, renal artery hemodynamics, and renal function in patients with coronary artery disease (CAD) and RAS.

Methods

In this single-center retrospective cohort, 57 CAD patients with RAS (July 2019–May 2025) underwent bilateral renal artery ultrasonography and ≥ 1 month follow-up. Patients received either PCSK9 inhibitor therapy (n = 25; evolocumab 140 mg biweekly + atorvastatin 20 mg/day) or standard statin therapy alone (n = 32; atorvastatin 20 mg/day as control). Changes in LDL-C, TC, TG, Lp(a), serum creatinine (Cr), and RAU_RRA/RAU_LRA were compared. Analyses included hierarchical clustering, principal component analysis (PCA), t-tests, and Spearman correlation.

Results

Between-group comparisons after treatment showed that the combination therapy group was significantly superior to the control group in terms of lipids, creatinine, and renal artery parameters (all P < 0.05), while Lp(a) showed an increasing trend. Within-group pre-post comparisons showed improving trends in various indicators, but only some lipid parameters reached statistical significance.

Conclusion

In this exploratory study, evolocumab plus statin was associated with improved lipids, renal artery hemodynamics, and potential renal benefit. Due to the small sample size, non-randomized design, and non-significant within-group creatinine change, results should be interpreted cautiously and validated in prospective studies.